Genetic Risk Assessment In Heart Failure: Impact Of The Genetic Variation Of G-Protein BETA 3 Subunit Polymorphism

Inventors: Dennis Michael McNamara: Manuel Worcel: Michael L. Sabolinski: Sang William Tam

Patent Number: 12/296,630

Abstract

The invention provides methods for treating various indications and diseases in a patient in need thereof, wherein the patient has a C825T polymorphism in the G protein beta3 subunit (GNB3), comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
View Google Patent Page
Download PDF